GE
In Brief This Week: Roche, Chembio, Danaher, and More
News items for the in vitro diagnostics industry for the week of March 2, 2020.
Danaher Prices $3.97B Senior Notes Offering
The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
Danaher Q3 Revenues Up 4 Percent
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
Danaher Offering €6.20B in Senior Notes
The company announced its European subsidiary priced an offering of €6.20 billion ($6.83 billion) in senior notes to fund part of its purchase of GE's Biopharma business.
Life Sciences, Diagnostics Drive Danaher Q2 Revenues Up 4 Percent
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.